JP2017537941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537941A5 JP2017537941A5 JP2017531577A JP2017531577A JP2017537941A5 JP 2017537941 A5 JP2017537941 A5 JP 2017537941A5 JP 2017531577 A JP2017531577 A JP 2017531577A JP 2017531577 A JP2017531577 A JP 2017531577A JP 2017537941 A5 JP2017537941 A5 JP 2017537941A5
- Authority
- JP
- Japan
- Prior art keywords
- fucnac
- mannac
- galnac
- pyr
- gal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001720 carbohydrates Chemical class 0.000 claims 11
- 241000894006 Bacteria Species 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000010324 immunological assay Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 0 C[C@](C(*)C1OC)OC(CO)C1O Chemical compound C[C@](C(*)C1OC)OC(CO)C1O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14197832.0 | 2014-12-12 | ||
| EP14197832 | 2014-12-12 | ||
| EP15163253 | 2015-04-10 | ||
| EP15163253.6 | 2015-04-10 | ||
| PCT/EP2015/060756 WO2016091399A1 (en) | 2014-12-12 | 2015-05-15 | Vaccines against streptococcus pneumoniae serotype 4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537941A JP2017537941A (ja) | 2017-12-21 |
| JP2017537941A5 true JP2017537941A5 (enExample) | 2018-06-21 |
| JP6622804B2 JP6622804B2 (ja) | 2019-12-18 |
Family
ID=53267330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531577A Active JP6622804B2 (ja) | 2014-12-12 | 2015-05-15 | ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型４に対するワクチン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10188718B2 (enExample) |
| EP (1) | EP3230297B1 (enExample) |
| JP (1) | JP6622804B2 (enExample) |
| WO (1) | WO2016091399A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX371087B (es) * | 2015-12-17 | 2020-01-16 | Max Planck Gesellschaft | Vacunas sintéticas contra el serotipo 2 de streptococcus pneumoniae. |
| US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| JP2025537898A (ja) | 2022-11-22 | 2025-11-20 | ファイザー・インク | コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用 |
| TW202527906A (zh) | 2023-09-14 | 2025-07-16 | 美商輝瑞股份有限公司 | 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016103771A (ru) * | 2013-07-07 | 2017-08-11 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Синтетические вакцины против streptococcus pneumoniae 1-го типа |
| EP2851092A1 (en) * | 2013-09-18 | 2015-03-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3 |
| CA2961694C (en) * | 2014-09-26 | 2022-11-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Vaccines against streptococcus pneumoniae serotype 8 |
| MX371087B (es) * | 2015-12-17 | 2020-01-16 | Max Planck Gesellschaft | Vacunas sintéticas contra el serotipo 2 de streptococcus pneumoniae. |
-
2015
- 2015-05-15 US US15/534,676 patent/US10188718B2/en active Active
- 2015-05-15 WO PCT/EP2015/060756 patent/WO2016091399A1/en not_active Ceased
- 2015-05-15 JP JP2017531577A patent/JP6622804B2/ja active Active
- 2015-05-15 EP EP15724583.8A patent/EP3230297B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wen et al. | Molecular epidemiology and evolution of Haemophilus influenzae | |
| JP2017532321A5 (enExample) | ||
| Jedrzejas | Pneumococcal virulence factors: structure and function | |
| Ogunniyi et al. | c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection | |
| Sethi | Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? | |
| Gunn et al. | Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence | |
| Ogunniyi et al. | The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo | |
| JP2020533438A5 (enExample) | ||
| JP2020533439A5 (enExample) | ||
| JP2020533437A5 (enExample) | ||
| JP2020533442A5 (enExample) | ||
| HRP20240847T1 (hr) | Novi polisaharid i njegove upotrebe | |
| JP2021535921A (ja) | 多価肺炎球菌ワクチン | |
| JP2017537941A5 (enExample) | ||
| Adamu et al. | Membrane proteins of Mycoplasma bovis and their role in pathogenesis | |
| JP2013079285A5 (enExample) | ||
| IL274500B2 (en) | Glycoconjugation process | |
| BRPI0920460A2 (pt) | eixo de torcao com espessura de parede variavel longitudinalmente | |
| CN111065417B (zh) | 免疫原性组合物 | |
| JP2015521202A5 (enExample) | ||
| François et al. | Antibody-based therapy to combat Staphylococcus aureus infections | |
| JP2016526564A5 (enExample) | ||
| Mirzaei et al. | Synthesis of conjugated PIA–rSesC and immunological evaluation against biofilm-forming Staphylococcus epidermidis | |
| WO2016198170A8 (en) | Vaccines against streptococcus pneumoniae serotype 5 | |
| Nieddu et al. | PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend? |